Therapies for improved diseases are expected to account for 69.2% of the market.
GlobalData said the Alzheimer’s disease (AD) market is expected to reach $17B by 2033 at a CAGR of 21.8%.
The industry’s expansion is attributed to the entry of modified disease therapy (DMTS), aging population, and the entry of symptomatic treatments for AD-related agitation and psychosis.
DMT is expected to account for 69.2% of the global market by 2033.
However, the unmet need remains therapeutic visits, says Philippa Salter, a neurology analyst at GlobalData.
“The new DMT is considered only moderately efficient, so not only will it progress slowly, but it still has a great opportunity to prevent more effective DMTs from disease, and prevention is the ultimate goal,” Salter added.
8mm = United States, France, Germany, Italy, Spain, United Kingdom, Japan and China
